Early trial halted for new prostate cancer combo therapy
NCT ID NCT05733351
Summary
This early-stage study aimed to test the safety and initial effectiveness of a new immunotherapy drug, vudalimab, when added to standard hormone therapies for men with advanced prostate cancer that has spread but still responds to hormone treatment. The trial was designed to see if this combination could help the immune system fight the cancer better. However, the study was terminated early after enrolling only 4 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IVB PROSTATE CANCER AJCC V8 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Emory University Hospital Midtown
Atlanta, Georgia, 30308, United States
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.